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Sickness behaviorSickness behavior appears to be the expression of a central motivational state that reorganizes an organism's
priorities to cope with infectious pathogens. To evaluate the possible participation of nitric oxide (NO) in
lipopolysaccharide-induced sickness behaviors, mice were submitted to the forced swim test (FST), open
ﬁeld test and dark–light box test. Food intake and corticosterone plasma levels were evaluated. Lipopolysac-
charide (LPS, 100 μg/kg; i.p.) administration increased the time spent ﬂoating in the FST and decreased loco-
motor activity in the open ﬁeld. Indeed, treatment with LPS decreased the total number of transitions
between the dark and light compartments of the apparatus. In addition, LPS reduced food intake and in-
creased corticosterone levels. Pretreatment with L-NAME (30 mg/kg; i.p.) or aminoguanidine (50 mg/kg;
i.p.) accentuated the behavioral changes induced by LPS in the FST, open ﬁeld and light–dark box tests as
well as induced an increment in hypophagia and in corticosterone levels. These ﬁndings conﬁrm previous ob-
servations that have reported LPS-induced sickness behaviors. In addition, they provide evidence that the
synthesis of NO modulates changes in depressive-like and exploratory behaviors in mice, which is supported
by the fact that NO synthase inhibitors also attenuate LPS-induced behavioral changes. In addition, the pres-
ent study suggests that NO may have a protective role, acting in an inhibitory feedback manner to limit
LPS-induced sickness behavior.
© 2012 Elsevier Inc. Open access under the Elsevier OA license. 1. Introduction
Sickness behavior is an expression of a motivational state trig-
gered by activation of the peripheral innate immune system where-
by an organism reorganizes its priorities to ﬁght infection (Parnet et
al., 2002; Dantzer et al., 2008; Dantzer, 2009). Sickness behavior is
easily induced in laboratory animals by the administration of endo-
toxins, which are the main active components of the outer mem-
brane of gram-negative bacteria. Peripheral administration of
endotoxin activates the immune system, resulting in the release of
pro-inﬂammatory cytokines and prostaglandins (Long et al., 1990;
Kelley et al., 2003; Engblom et al., 2002; Rorato et al., 2009; de
Paiva et al., 2010). These peripherally produced cytokines gain ac-
cess to the brain and produce the classical symptoms of sickness be-
havior, including reduction in locomotor activity and exploratory
behaviors, anorexia and anhedonia (Engblom et al., 2002; Frenois
et al., 2007). In addition, it has been demonstrated that upon stimu-
lation by endotoxin and cytokines, nitric oxide synthase (NOS)ciences, Federal University of
-000, Alfenas, MG, Brazil. Tel.:
aiva).
vier OA license. becomes expressed, leading to the production of large amounts of
nitric oxide (NO) in peripheral tissues and in the brain (Moncada et
al., 1991; Giusti-Paiva et al., 2005; Mollace et al., 2005).
NO is produced from L-arginine by three different isoforms of NOS,
two of which are expressed constitutively, endothelial (eNOS) and
neuronal (nNOS) (Mollace et al., 2005). Endotoxin induces the ex-
pression of another calcium-independent inducible isoform of NOS
(iNOS) in a number of tissues including the brain (Moncada et al.,
1991; Mollace et al., 2005; Cauwels, 2007). Pharmacological inhibi-
tion of NOS can be used to elucidate the contribution of NO, and pre-
vious reports support both a detrimental and beneﬁcial role of NO
during immune challenges. An increase in the amount of NO pro-
duced by iNOS might play a pivotal role in the pathophysiology of
sepsis (Thiemermann, 1997; Szabo, 1996; Vincent et al., 2000;
Cauwels, 2007).
Although a signiﬁcant volume of literature indicates that cytokines
and prostaglandins are important mediators of sickness behavior
(Dunn and Swiergiel, 2005; Dantzer et al., 2008; de Paiva et al., 2010),
there is a lack of data on the role of NO in endotoxin-induced sickness
behavior. To evaluate the possible participation of NO in LPS-induced
sickness behaviors, mice were submitted to well-accepted tests to eval-
uate depressive-like and exploratory behaviors, including the forced
swim test (FST), open ﬁeld test and dark–light box test.
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Fig. 1. Effects of pretreatment with vehicle, L-NAME (30 mg/kg) or aminoguanidine (AG,
50 mg/kg) on time spent ﬂoating in the forced swim test (n=12 animals per group),
which were measured 2 h after administration of either lipopolysaccharide (LPS) or sa-
line. Each column represents themeanwith S.E.M. The symbols denote signiﬁcance levels:
**pb0.01; ***pb0.001when comparedwith the control groups; # pb0.05when compared
with the vehicle plus LPS group.
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2.1. Animals
Adult male Swiss mice (22–30 g) were obtained from the Central
Animal Facility of the Federal University of Alfenas. Animals were
housed under controlled light (12:12 h light–dark cycle; lights on at
06:00 am) and temperature conditions (23±1 °C) with access to
water and food ad libitum. Animals were allowed to habituate to the
housing facilities for at least 1 week before the experiments began.
Behavioral studies were conducted in a quiet room between 09:00
and 11:00 a.m. to avoid circadian variation. All experiments were
conducted in accordance with the Declaration of Helsinki addressing
the welfare of experimental animals and with the approval of the
Ethics Committee of the Federal University of Alfenas (protocol
#0178/2008).
2.2. Experimental procedures
In the animal room, the mice were pretreated with non-selective
NOS inhibitor (Nϖ-L-nitro-arginine methyl ester; L-NAME, 30 mg/kg),
or a relatively selective iNOS inhibitor (aminoguanidine, 50 mg/kg), or
vehicle (0.9% NaCl) 30 min before injections of lipopolysaccharide
(LPS) serotype 026:B6 (100 μg/kg; i.p.) or saline (0.9%NaCl). The behav-
ioral tests were performed 120 min after the LPS treatment. These time
points were chosen on the basis of previous behavioral, endocrine and
neurochemical studies (Dunn and Swiergiel, 2005; Rorato et al., 2009;
de Paiva et al., 2010). The doses of L-NAME and aminoguanidine used
in the present study are in agreement with the doses commonly used
in other reports that injected these compounds peripherally (Giusti-
Paiva et al., 2004). All drugs were purchased from Sigma-Aldrich Co.
and dissolved in sterile isotonic saline.
2.2.1. Forced swim test
This test was performed according to the method developed by
Porsolt et al. for mice. Mice (n=12 per group) were placed in a ver-
tical glass cylinder (26 cm high, 12 cm diameter) ﬁlled with 25 °C
water to a depth of 16 cm.Water depth was chosen to ensure that an-
imals swam or ﬂoated without their hind limbs or tail touching the
bottom. Each mouse was placed in the cylinder for 6 min, and the du-
ration of ﬂoating (i.e., the time during which mice made only the
smallest movements necessary to keep their heads above water)
was scored. As suggested by Porsolt et al. (1977), only the data scored
during the last 4 min were analyzed and presented (Porsolt et al.,
1977; Dunn and Swiergiel, 2005; de Paiva et al., 2010).
2.2.2. Open ﬁeld behavioral test
Locomotor activity was quantiﬁed for 5 min in an open ﬁeld box,
consisting of white Plexiglas 60×60 cm in diameter with a ﬂoor di-
vided into 16 squares. Previous studies have indicated that this
time-period was sufﬁcient to produce differences between treatment
groups. Furthermore, after 5 min, the mice habituate to the appara-
tus, thereby decreasing the differences between groups. Four squares
were deﬁned as the center and the 12 squares along the walls were
considered the periphery. Each mouse (n=10 per group) was gently
placed in the exact center of the box. Activity was scored as a line
crossing when a mouse removed all four paws from one square and
entered another. Line crossings among the central four squares or
among the peripheral 12 squares of the open ﬁeld were counted sep-
arately (Dunn and Swiergiel, 2005; de Paiva et al., 2010).
2.2.3. Light–dark box test
The apparatus consisted of a Plexiglas rectangular box (48 cm
long×24 cm wide×24 cm high) divided into a dark region (24 cm
long) and a light region (24 cm long). The light and dark regions
were separated by an opening (8.0×8.0 cm) that allowed the animalsto move between the two compartments. The dark region was made
of black Plexiglas and covered with a black lid. The light portion was
made of white Plexiglas, and a 60 W light was positioned directly
over it. On the day of testing, each mouse was transported individual-
ly from the housing room to the testing room. Each mouse (n=10
per group) was placed in the light compartment and allowed to
move freely between the two compartments. The behavior was
video-recorded for a total of 5 min, and the videotapes were scored
for latency to the ﬁrst transition and the number of transitions be-
tween the light and dark compartments (Lacosta et al., 1999; de
Paiva et al., 2010).2.2.4. Feeding behavior
The animals (n=10 per group) fasted for 12 h before receiving in-
jections. Immediately after injections, a fresh supply of pre-weighed
food was given. Food intake was calculated at 2, 4, 6 and 24 h after
the injection by measuring the difference between the pre-weighed
standard chow available and the weight of chow and spilled crumbs
at each time point. Changes in body weight were measured by
weighing the animals at the beginning of the experiment as well as
before and after an experimental day (Rorato et al., 2009; Soncini
et al., 2012).2.2.5. Plasma corticosterone assay
Trunk blood was collected from animals 2 h after LPS or saline
injections in chilled heparinized tubes and was centrifuged at
3000 rpm for 15 min at 4 °C. Plasma was collected and stored at
−20 °C. Plasma corticosterone was measured by radioimmunoassay.2.2.6. Statistical analysis
The data obtained were analyzed using the GraphPad software
program Version 4.0 and expressed as the mean±S.E.M. Statistically
signiﬁcant differences among groups were calculated by the applica-
tion of an analysis of variance (ANOVA) followed by the Newman–
Keuls test. P-values less than 0.05 (pb0.05) were considered
signiﬁcant.
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Fig. 2. Effects of pretreatment with vehicle, L-NAME (30 mg/kg) or aminoguanidine
(AG, 50 mg/kg) on peripheral (A), central (B) and total (C) line crossings in the open
ﬁeld test (n=10 per group), which were measured 2 h after administration of either
LPS or saline. Each column represents the mean with S.E.M. The symbols denote signif-
icance levels: *pb0.05;**pb0.01; ***pb0.001 when compared with the control groups;
# pb0.05; ## pb0.01 when compared with the vehicle plus LPS group.
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3.1. Activity in the forced swim test
L-NAME and aminoguanidine did not alter the immobility period
in the FST in saline treated mice. There was a signiﬁcant increase in
the immobility period 120 min after administration of LPS in the
FST (F5,71=16.94; pb0.01; Fig. 1) in mice pretreated with vehicle.
The administration of LPS in mice previously treated with L-NAME
or aminoguanidine caused a signiﬁcantly higher immobility period
in FST (pb0.05), in comparison with the vehicle plus LPS group.
3.2. Activity in the open ﬁeld test
Fig. 2 shows the effect of LPS on number of line crossings in the
open ﬁeld, and the modulatory effects of NOS inhibition.
Pretreatment with L-NAME or aminoguanidine did not signiﬁcantly
change the locomotor activity in the open ﬁeld 120 min after i.p. sa-
line injection. On the other hand, LPS signiﬁcantly decreased the
number of line crossings in the center (F5,59=11.9, pb0.01; Fig. 2A)
and in the periphery (F5,59=16.3, pb0.01; Fig. 2B), as well as the
total number of line crossings (F5,59=20.28, pb0.001; Fig. 2C). The
number of line crossings in periphery and center of open ﬁeld was
even smaller in the mice pretreated with NOS inhibitors (pb0.05).
3.3. Behavior in the light–dark box test
The amount of time spent before the ﬁrst transition in the black–
white box as well as the number of entries into the light compartment
were evaluated (Fig. 3). There were no signiﬁcant differences in latency
to the ﬁrst transition after LPS administration (Fig. 3A). However, there
was a signiﬁcant difference in the number of transitions between the
light and dark compartments (F5,59=28.8; pb0,001; Fig. 3B). The ad-
ministration of LPS in mice previously treated with L-NAME or
aminoguanidine caused a signiﬁcant increase in latency to the ﬁrst tran-
sition (F5,59=4.01; p=0,0036; Fig. 3A), and an accentuated decrease in
the number of transitions between the compartments, compared with
the vehicle plus LPS group (Fig. 3B; pb0.05).
3.4. Food intake and body weight
LPS signiﬁcantly decreased food intake 4 h after injection (F7,79=
3.65; pb0.01; Fig. 4A), overnight food intake (F7,79=6.466; pb0.001;
Fig. 4A) and body weight (F7,79=3.842; pb0.01; Fig. 4B). Further-
more, pretreatment with L-NAME or aminoguanidine signiﬁcantly
accentuated both hypophagic effects (pb0.05) and reduced body
weight gain (pb0.05) induced by LPS.
3.5. Corticosterone plasma levels
Pretreatment with L-NAME or aminoguanidine did not signiﬁcantly
change the corticosterone plasma levels 2 h after i.p. saline injection;
however, LPS injections resulted in an increase in the corticosterone
plasma levels at this time. The administration of LPS in mice previously
treated with L-NAME or aminoguanidine caused a signiﬁcant increase
in corticosterone secretion, compared with the control group (Fig. 5).
4. Discussion
The present study conﬁrms previous observations that LPS can in-
duce sickness behavior. These ﬁndings also provide evidence that NO
acts as modulator for the development of depressive-like and explor-
atory behaviors in mice because non-selective NOS inhibition or se-
lective inhibition of iNOS accentuated LPS-induced the behavioral
changes.
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Fig. 3. Effects of pretreatment with vehicle, L-NAME (30 mg/kg) or aminoguanidine
(AG, 50 mg/kg) on latency to the ﬁrst transition (A) and number of transitions (B) in
the light–dark box test (n=10 per group), which were measured 2 h after administra-
tion of either LPS or saline. Each column represents the mean with S.E.M. The symbols
denote the signiﬁcance levels: *pb0.05; ***pb0.001 when compared with the control
groups; # pb0.05 when compared with the vehicle plus LPS group.
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ﬂoating in the FST and depressed the locomotor activity in the open
ﬁeld. These effects are characteristic of treatments that have been
shown to induce depression-like behavior, and an accompanying def-
icit in locomotor activity would most likely affect performance in the
FTS (Dunn and Swiergiel, 2005; de Paiva et al., 2010). In addition to
promoting illness, LPS elicited an anxiogenic-like response in the
light–dark box test. Indeed, treatment with LPS decreased the total
number of transitions between dark and light compartments of the
apparatus, which is a pattern believed to reﬂect anxiety. The proposi-
tion that LPS elicits anxiety is consistent with these ﬁndings that LPS
induced an increase in corticotrophin-releasing factor (CRF) secre-
tion, a hormone known to promote anxiety and activation of
hypothalamus-pituitary-adrenal axis, as evidenced by increased cor-
ticosterone levels (Turnbull and Rivier, 1999; Rorato et al., 2009;
Benedetti et al., 2011).
Activation of the immune system in response to LPS produced
neural, neuroendocrine, and behavioral effects. These effects are me-
diated by circulating cytokines that inﬂuence brain activity by induc-
ing the expression of neuronal NOS (nNOS) and inducible NOS (iNOS)in the hypothalamus, and the expression of cyclooxygenase (COX)-2
and microsomal prostaglandin E synthase-1 (mPGES-1) in brain vas-
cular cells (Engblom et al., 2002, 2003; Parnet et al., 2002). Previous
work has indicated that fever is mediated by increased production
of prostaglandin E2 (PGE2) that is synthesized along the blood–brain
barrier (Engblom et al., 2003), which activates a population of target
neurons in the thermoregulatory center of the brain with speciﬁc
PGE2 receptors (Ushikubi et al., 1998). In addition, sickness behavior
in response to LPS has been shown to be absent or greatly attenuated
in mice pre-treated with inhibitors of cyclooxygenase, thereby
suggesting that sickness behavior induced by LPS is mainly prosta-
glandin dependent and is most likely mediated by a mechanism sim-
ilar to febrile response mechanisms (Ushikubi et al., 1998; Dallaporta
et al., 2007; de Paiva et al., 2010). At the behavioral level, sickness be-
havior is a motivational state that reorganizes an organism's priorities
to cope with infectious pathogens; however, the mechanisms under-
lying sickness behaviors have not been fully elucidated (Dantzer,
2009; Kelley et al., 2003).
LPS is a potent inducer of iNOS. Large amounts of NO and
peroxynitrite, among other factors, are responsible for the hypoten-
sion, vasoplegia, apoptosis, lactic acidosis and multi-organ failure ob-
served in the late phases of endotoxic shock. The data supporting
both a detrimental and beneﬁcial role of NO in septic shock have
changed the scientiﬁc impression of this molecule. Indeed, experi-
mental and clinical use of NOS inhibitors, which do not differentiate
clearly between constitutive endothelial NOS and iNOS, prevents
LPS-induced hypotension (Giusti-Paiva et al., 2002, 2004; Vona-
Davis et al., 2002). However, many detrimental effects of NOS inhibi-
tors are also reported, including increases in pulmonary resistance,
decreases in cardiac output and organ perfusion, and even an increase
in mortality in experimental animals (Boyle et al., 2000; Metcalf et al.,
2002; Vona-Davis et al., 2002). For this reason, selective iNOS inhibi-
tors, such as aminoguanidine or thiourea derivatives, might be pre-
ferred over nonselective NOS inhibitors for the treatment of septic
shock (Cauwels, 2007). However, because iNOS-derived NO is in-
volved in multiple pathways, selective iNOS inhibition may be not
as beneﬁcial as expected. On the other hand, previous studies have
demonstrated a relation between functional protection of inhaled
NO and reduced leukocyte adhesion and emigration in inﬂammatory
lung injury (Guidot et al., 1995; Trzeciak et al., 2008). Concurrently,
we found that the preservation of oxygenation in animals given NO
inhalation was associated with less pulmonary sequestration of leu-
kocytes. Accordingly, inhalation of NO gas or NO-donors in septic
shock might be a complementary treatment to the use of NOS
inhibitors.
In addition to the constitutive isoforms nNOS, iNOS expression has
also been detected in the brain during immune challenge. iNOS is
preferentially expressed in macrophages and is up-regulated in re-
sponse to a variety of inﬂammatory stimuli; however, iNOS has
been reported in the brain following endotoxin administration
(Minc-Golomb et al., 1994; Harada et al., 1999). Harada et al. (1999)
have demonstrated that LPS activates both nNOS and iNOS gene ex-
pression and activity in the hypothalamus, with a delayed
time-course expression of iNOS compared with nNOS. Overall, there
is a profound increase in NO production derived from both nNOS
and iNOS in the brain after systemic inﬂammation or sepsis
(Minc-Golomb et al., 1994; Harada et al., 1999). Despite an increase
in NO production, including in the brain, during endotoxemia in
mice and because NOS inhibitors crosses the blood–brain barrier
(Uribe et al., 1999; Mahar Doan et al., 2000), does NO can play a
role in the central mechanisms the involvement of sickness behavior
induced by LPS.
Previous reports suggest that one of the roles of endogenous NO
might be to restrain activation of the hypothalamic-pituitary-adrenal
(HPA) axis during periods of increased cytokine and/or neuropeptide
productivity, such as during immune stimulation (Uribe et al., 1999;
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Fig. 4. Effects of pretreatment with vehicle, L-NAME (30 mg/kg) or aminoguanidine (AG, 50 mg/kg) on food intake (A), and body weight change (B) evaluated at 24 h after admin-
istration of either LPS or saline. Each column represents the mean with S.E.M. The symbols denote signiﬁcance levels: *pb0.05; when compared with the control groups; # pb0.05;
when compared with the vehicle plus LPS group.
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al., 2009). Glucocorticoids have been suggested to play an important
role in organisms coping with unpredictable events. During such
events, glucocorticoids function to maintain allostasis or physiological
stability (McEwen and Wingﬁeld, 2003; Goymann and Wingﬁeld,
2004; Romero et al., 2009). In our study, animals treated with nitric
oxide synthase inhibitors prior to endotoxin administration displayed
an increase in corticosterone secretion and accentuated depression-
like behavior, anxiety and hypophagia. This ﬁnding suggests that NO
is involved in the development of sickness behavior induced by LPS.
In conclusion, using a mouse model for acute systemic inﬂamma-
tion, we have shown that pharmacologically blocking NOS results in0
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Fig. 5. Effects of pretreatment with vehicle, L-NAME (30 mg/kg) or aminoguanidine (AG,
50 mg/kg) on corticosterone plasma levels after administration of either LPS or saline.
Each column represents the mean with S.E.M. The symbols denote signiﬁcance levels:
*pb0.05; ***pb0.001 when compared with the control groups; # pb0.05; ### pb0.001
when compared with the vehicle plus LPS group.accentuated LPS-induced behavioral changes. In addition, the present
study suggests that NO may have a protective role, acting in an inhib-
itory feedback manner, to limit LPS-induced sickness behavior.
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